Lyell Immunopharma to present ronde-cel data at EHA 2026 congress

June 4, 2026 4:05 PM

Lyell Immunopharma Inc. (NASDAQ: LYEL) will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found